Browse > Article

The Stimulatory Effect of PDE Inhibitors on $PGE_2$-Induced Osteoclastogenesis  

No, A-Long-Sae-Mi (College of Pharmacy, Sookmyung Women’s University)
Yim, Mi-Jung (College of Pharmacy, Sookmyung Women’s University)
Publication Information
YAKHAK HOEJI / v.51, no.4, 2007 , pp. 235-238 More about this Journal
Abstract
To determine the regulatory roles of phosphodiesterase (PDE) inhibitors on $PGE_2$-induced osteoclastogenesis, we investigated the effect of PDE inhibitors on osteoclast formation in the presence of $PGE_2$. Among PDE isozyme specific inhibitors, milrinone, a selective PDE3 inhibitor, and rolipram, a specific PDE4 inhibitor, increased $PGE_2$-induced osteoclast formation in cocultures of mouse bone marrow cells and osteoblasts. To verify that whether the PDE3 and PDE4 inhibitors act indirectly on osteoblasts, we measured the concentration of intracellular cAMP in osteoblasts. Treatment of milrinone or rolipram increased $PGE_2$-stimulated cAMP levels in osteoblasts. Furthermore, northern blot analysis revealed that the PDE3 and PDE4 inhibitors works synergistically with $PGE_2$ to increase the expression of TRANCE mRNA in osteoblasts. On the contrary, the PDE3 and PDE4 inhibitors did not augment the number of osteoclasts differentiated from bone marrow cells by $PGE_2$. In conclusion, the stimulation of $PGE_2$-induced osteoclast formation by the PDE3 and PDE4 inhibitors are attributable to their indirect effect on osteoblasts, not to their direct effect on bone marrow-derived osteoclast precursors.
Keywords
Phosphodiesterase; osteoblast; osteoclast;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Lacey, D. L., Timms, E., Tan, H. L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y. X., Kaufman, S., Sarosi, I., Shalhoub, V., Senaldi, G., Guo, J., Delaney, J. and Boyle, W. J. : Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165 (1998)
2 Wani, M. R, Fuller, K., Kim, N. S., Choi, Y. and Chambers, T. : Prostaglandin $E_2$ cooperates with TRANCE in osteoclast induction from hemopoietic precursors: synergistic activation of differentiation, cell spreading, and fusion. Endocrinology 140, 1927 (1999)
3 Li, L., Pettit, A. R., Gregory, L. S. and Forwood, M. R. : Regulation of bone biology by prostaglandin endoperoxide H synthases (PGHS): a rose by any other name. Cytokine Growth Factor Rev. 17, 203 (2006)   DOI   ScienceOn
4 Antoni, F. A. : Molecular diversity of cyclic AMP signaling. Front Neuroendocrinol. 21, 103 (2000)
5 Park, H., Young Lee, S., Lee, D. S. and Yim, M. : Phosphodiesterase 4 inhibitor regulates the TRANCE/OPG ratio via COX-2 expression in a manner similar to PTH in osteoblasts. Biochem. Biophys. Res. Commun. 354, 178 (2007)
6 Fu, Q., Jilka, R. L., Manolagas, S. C. and O'Brien, C. A. : Parathyroid hormone stimulates receptor activator of NF-${\kappa}B$ ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J. BioI. Chem. 277, 48868 (2002)
7 Kondo, H., Guo, J. and Bringhurst, F. R. : Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. J. Bone Miner. Res. 17, 1667 (2002)
8 Essayan, D. M. : Cyclic nucleotide phosphodiesterases. J. Allergy Clin. Immunol. 108, 671 (2001)   DOI   ScienceOn
9 Takahashi, N., Akatsu, T., Udagawa, N., Sasaki, T., Yamaguchi, A., Moseley, J. M., Martin, T. J. and Suda, T. : Osteoblastic cells are involved in osteoclast formation. Endocrinology 123, 2600 (1988)
10 Wong, B. R., Rho, J., Arron, J., Robinson, E., Orlinick. J., Chao, M., Kalachikov, S., Cayani, E., Bartlett, F S. 3rd, Frankel, W. N., Lee, S. Y. and Choi, Y. : TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. BioI. Chem. 272, 25190 (1997)
11 Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T. and Martin, T. J. : Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20, 345 (1999)
12 Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T., Higashio, K., Udagawa, N., Takahashi, N. and Suda, T. : Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. SCI. USA 95, 3597 (1998)
13 Kaji, H., Sugimoto, T., Kanatani, M., Fukase, M., Kumegawa, M. and Chihara, K. : Prostaglandin $E_2$ stimulates osteoclast-like cell formation and bone-resorbing activity via osteoblasts: role of cAMP-dependent protein kinase.J. Bone Miner. Res. 11, 62 (1996)
14 Take, I., Kobayashi, Y., Yamamoto, Y., Tsuboi, H., Ochi, T., Uematsu, S., Okafuji, N., Kurihara, S., Udagawa, N. and Takahashi, N. : Prostaglandin $E_2$ strongly inhibits human osteoclast formation. Endocrinology 146, 5204 (2005)   DOI   ScienceOn
15 Bender, A. T. and Beavo, J. A. : Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacal Rev. 58, 488 (2006)   DOI   ScienceOn